Structured abstract
Objective To determine whether naturally occurring autoantibodies against the prion protein are present in individuals with genetic prion disease mutations and controls, and if so, whether they are protective against prion disease.
Methods In this case-control study, we collected 124 blood samples from individuals with a variety of pathogenic PRNP mutations and 78 control individuals with a positive family history of genetic prion disease but lacking disease-associated PRNP mutations. Antibody reactivity was measured using an indirect ELISA for the detection of human IgG1-4 antibodies against wild-type human prion protein. Multivariate linear regression models were constructed to analyze differences in autoantibody reactivity between a) PRNP mutation carriers versus controls and b) asymptomatic versus symptomatic PRNP mutation carriers. Robustness of results was examined in matched cohorts.
Results We found that antibody reactivity was present in a subset of both PRNP mutation carriers and controls. Autoantibody levels were not influenced by PRNP mutation status nor clinical manifestation of prion disease. Post hoc analyses showed anti-PrPC autoantibody titers to be independent of personal history of autoimmune disease and other immunological disorders, as well as PRNP codon 129 polymorphism.
Conclusions Pathogenic PRNP variants do not notably stimulate antibody-mediated anti-PrPC immunity. Anti-PrPC IgG autoantibodies are not associated with the onset of prion disease. The presence of anti-PrPC autoantibodies in the general population without any disease-specific association suggests that relatively high titers of naturally occurring antibodies are well tolerated. Clinicaltrials.gov identifier NCT02837705.
Competing Interest Statement
Dr. Frontzek received an unrestricted grant by Ono Pharmaceuticals and was funded by the Theodor Ida Herzog-Egli Stiftung. Dr. Meisl is funded by a Ramon Jenkins Research Fellowship at Sidney Sussex College. Dr. Minikel has received research support in the form of charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals and has consulted for Deerfield Management. Dr. Knowles received financial support by the EPSRC, BBSRC, ERC and the Frances and Augustus Newman Foundation. Dr. Lindner was funded by the National Organization for Rare Diseases. Dr. Hornemann is the recipient of grants from SystemsX.ch (SynucleiX) and the innovations commission of the University Hospital of Zurich. Dr. Aguzzi is the recipient of an Advanced Grant of the European Research Council (ERC 250356) and is supported by grants from the Swiss National Foundation (SNF, including a Sinergia grant), the Swiss Initiative in Systems Biology, SystemsX.ch (PrionX, SynucleiX), the Klinische Forschungsschwerpunkte (KFSPs) "small RNAs" and "Human Hemato-Lymphatic Diseases", and a Distinguished Investigator Award of the Nomis Foundation.
Clinical Trial
NCT02837705
Funding Statement
The authors would like to thank the EPSRC, BBSRC, ERC and the Frances and Augustus Newman Foundation for financial support. This work was supported by the programs “Investissements d’avenir” ANR-10-IAIHU-06, “Santé Publique France” and supported by grants from NIH (R01NS103848), and CDC (UR8/CCU515004). Karl Frontzek received funding from the Theodor Ida Herzog-Egli Stifung and an unrestricted grant by Ono Pharmaceuticals. Georg Meisl is funded by a Ramon Jenkins Research Fellowship at Sidney Sussex College. Adriano Aguzzi is the recipient of an Advanced Grant of the European Research Council (ERC 250356) and is supported by grants from the Swiss National Foundation (SNF, including a Sinergia grant), the Swiss Initiative in Systems Biology, SystemsX.ch (PrionX, SynucleiX), the Klinische Forschungsschwerpunkte (KFSPs) "small RNAs" and "Human Hemato-Lymphatic Diseases", and a Distinguished Investigator Award of the Nomis Foundation. Collection of samples at Massachusetts General Hospital was funded by Prion Alliance. The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Footnotes
Author disclosures
Dr. Frontzek received an unrestricted grant by Ono Pharmaceuticals and was funded by the Theodor Ida Herzog-Egli Stiftung.
Dr. Carta reports no disclosures.
Dr. Losa reports no disclosures.
Ms. Epskamp reports no disclosures.
Dr. Meisl is funded by a Ramon Jenkins Research Fellowship at Sidney Sussex College.
Ms. Anane reports no disclosures.
Dr. Brandel reports no disclosures.
Dr. Camenisch reports no disclosures.
Dr. Castillas reports no disclosures.
Dr. Roiter reports no disclosures.
Dr. Haïk reports no disclosures.
Dr. Minikel has received research support in the form of charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals and has consulted for Deerfield Management.
Dr. Knowles received financial support by the EPSRC, BBSRC, ERC and the Frances and Augustus Newman Foundation.
Dr. Lindner was funded by the National Organization for Rare Diseases.
Dr. Lutterotti reports no disclosures.
Dr. Safar reports no disclosures.
Dr. Sanchez-Valle reports no disclosures.
Dr. Žáková reports no disclosures.
Dr. Hornemann is the recipient of grants from SystemsX.ch (SynucleiX) and the innovations commission of the University Hospital of Zurich.
Dr. Aguzzi is the recipient of an Advanced Grant of the European Research Council (ERC 250356) and is supported by grants from the Swiss National Foundation (SNF, including a Sinergia grant), the Swiss Initiative in Systems Biology, SystemsX.ch (PrionX, SynucleiX), the Klinische Forschungsschwerpunkte (KFSPs) “small RNAs” and “Human Hemato-Lymphatic Diseases”, and a Distinguished Investigator Award of the Nomis Foundation.
Data Availability
The study participants, if they have not undergone predictive testing themselves, participated under the condition of not knowing their PRNP genotype. Due to the relatively small sample size and risk of de-identification, all raw study data involving human participants was made available to the editors and reviewers but will not be made available publicly. DNA sequences of gene blocks used for construction of humanized antibodies and human PrPC-AviTagTM are available from the first author upon reasonable request.
